Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programme

D. Morrone, L. Dinshaw, JAG. de Souza, C. Chen, P. Kirchhof, Y. Koretsune, L. Pecen, CC. Wang, T. Yamashita, M. Unverdorben, R. De Caterina

. 2025 ; 5 (2) : oeaf004. [pub] 20250328

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008160

AIMS: The 2020 European Society of Cardiology (ESC)-atrial fibrillation (AF) guidelines recommend a risk-based approach to oral anticoagulation (OAC) therapy in patients with AF; however, it is unknown if current practice aligns with these recommendations. This study assessed the associated effectiveness and safety of edoxaban in patients with AF according to the 2020 ESC-AF guidelines and the approved label in routine clinical care. METHODS AND RESULTS: The Global ETNA-AF programme is a large prospective, noninterventional programme evaluating safety and effectiveness of edoxaban. Baseline characteristics and 2-year clinical event data were analysed in subgroups, defined by ESC-AF guidelines indication of OAC therapy according to CHA2DS2-VASc score [no OAC to be considered, OAC should be considered (2 for females/1 for males), and OAC recommended (≥3 for females/≥2 for males)] and modified HAS-BLED score [(≥3 (bleeding risk high) vs. <3 (bleeding risk low)]. Of 19 960 patients included, 16 912 (84.7%) were categorized as OAC recommended and 2501 (12.5%) as OAC should be considered; 547 (2.7%) were in the no OAC to be considered group. In the OAC recommended group, 12 006 (71.0%) had high bleeding risk. Clinical event rates were <5%/year across all risk groups, even in the OAC recommended and high bleeding risk groups. In the OAC recommended and high bleeding risk groups, patients had low ischaemic stroke and bleeding event rates, regardless of receiving the 30 or 60 mg dose. CONCLUSION: This study demonstrated that edoxaban use in patients with AF largely aligns with 2020 ESC-AF guidelines, while maintaining low clinical event rates. REGISTRATION: Europe (NCT02944019), Japan (UMIN000017011), and Korea/Taiwan (NCT02951039).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008160
003      
CZ-PrNML
005      
20250422095811.0
007      
ta
008      
250408s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ehjopen/oeaf004 $2 doi
035    __
$a (PubMed)40161305
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Morrone, Doralisa $u Department of Surgery, Medical, Molecular, and Critical Area Pathology, University of Pisa, Via Paradisa 2, Pisa 50124, Italy $1 https://orcid.org/0000000296676931
245    10
$a Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programme / $c D. Morrone, L. Dinshaw, JAG. de Souza, C. Chen, P. Kirchhof, Y. Koretsune, L. Pecen, CC. Wang, T. Yamashita, M. Unverdorben, R. De Caterina
520    9_
$a AIMS: The 2020 European Society of Cardiology (ESC)-atrial fibrillation (AF) guidelines recommend a risk-based approach to oral anticoagulation (OAC) therapy in patients with AF; however, it is unknown if current practice aligns with these recommendations. This study assessed the associated effectiveness and safety of edoxaban in patients with AF according to the 2020 ESC-AF guidelines and the approved label in routine clinical care. METHODS AND RESULTS: The Global ETNA-AF programme is a large prospective, noninterventional programme evaluating safety and effectiveness of edoxaban. Baseline characteristics and 2-year clinical event data were analysed in subgroups, defined by ESC-AF guidelines indication of OAC therapy according to CHA2DS2-VASc score [no OAC to be considered, OAC should be considered (2 for females/1 for males), and OAC recommended (≥3 for females/≥2 for males)] and modified HAS-BLED score [(≥3 (bleeding risk high) vs. <3 (bleeding risk low)]. Of 19 960 patients included, 16 912 (84.7%) were categorized as OAC recommended and 2501 (12.5%) as OAC should be considered; 547 (2.7%) were in the no OAC to be considered group. In the OAC recommended group, 12 006 (71.0%) had high bleeding risk. Clinical event rates were <5%/year across all risk groups, even in the OAC recommended and high bleeding risk groups. In the OAC recommended and high bleeding risk groups, patients had low ischaemic stroke and bleeding event rates, regardless of receiving the 30 or 60 mg dose. CONCLUSION: This study demonstrated that edoxaban use in patients with AF largely aligns with 2020 ESC-AF guidelines, while maintaining low clinical event rates. REGISTRATION: Europe (NCT02944019), Japan (UMIN000017011), and Korea/Taiwan (NCT02951039).
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dinshaw, Leon $u Universitäres Herzzentrum Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany $1 https://orcid.org/0000000214735716
700    1_
$a de Souza, José Antonio Gordillo $u Daiichi Sankyo Europe GmbH, Zielstattstraße 48, Munich 81379, Germany
700    1_
$a Chen, Cathy $u Daiichi Sankyo, Inc., 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA
700    1_
$a Kirchhof, Paulus $u Center for Cardiovascular Research, University of Birmingham and SWBH and UHB NHS Trusts, Birmingham B15 2TT, UK $u Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistraße 52, Hamburg 20246, Germany $u German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany $1 https://orcid.org/0000000218810197
700    1_
$a Koretsune, Yukihiro $u National Hospital Organization Osaka National Hospital, 2 Chome-1-14 Hoenzaka, Chuo Ward, Osaka 540-0006, Japan $1 https://orcid.org/0000000316508362
700    1_
$a Pecen, Ladislav $u Institute of Computer Science of the Academy of Sciences of the Czech Republic, Pod Vodárenskou věží 2, Prague 18200, Czech Republic $1 https://orcid.org/0000000198273178
700    1_
$a Wang, Chun-Chieh $u Division of Cardiology, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital, No. 5, Fuxing St, Guishan District, Taoyuan 333, Taiwan
700    1_
$a Yamashita, Takeshi $u Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-ku, Tokyo 106-0031, Japan $1 https://orcid.org/0000000225448464
700    1_
$a Unverdorben, Martin $u Daiichi Sankyo, Inc., 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA $1 https://orcid.org/0000000236018187
700    1_
$a De Caterina, Raffaele $u Chair of Cardiology, University of Pisa, and Cardiology 1 Division, Pisa University Hospital, Via Paradisa 2, Pisa 56125, Italy $u Fondazione VillaSerena per la Ricerca, Via Leonardo Petruzzi 42, Città Sant'Angelo, Pescara 65013, Italy $1 https://orcid.org/000000031637574X $7 uk2006353696
773    0_
$w MED00213975 $t European heart journal open $x 2752-4191 $g Roč. 5, č. 2 (2025), s. oeaf004
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40161305 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095813 $b ABA008
999    __
$a ok $b bmc $g 2306290 $s 1245235
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 5 $c 2 $d oeaf004 $e 20250328 $i 2752-4191 $m European heart journal open $n Eur Heart J Open $x MED00213975
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Možnosti archivace